J Endod:使用不同载体对white MTA理化性能、抗菌性能和生物特性的影响

2017-03-28 MedSci MedSci原创

这篇研究的目的是为了在white MTA混有水溶性或含牛蒡和茜草(植物提取物)的丙二醇浸膏剂后,评估其理化性能、抗菌性能和生物特性改变。

这篇研究的目的是为了在white MTA混有水溶性或含牛蒡和茜草(植物提取物)的丙二醇浸膏剂后,评估其理化性能、抗菌性能和生物特性改变。

方法:凝固时间的测试是按照美国测试和材料协会266/2008执行。流动性的测试是按照美国国家标准协会/美国牙医联盟57/2012标准规格执行。其他参数评估如下:micro-CT检测容积改变;pH水平和钙离子释放检测在3 h、1、3、7和15天;抗菌活性通过牙本质去污法检测小管内的粪肠球菌活性,并通过激光共聚焦显微镜进行验证;生物相容性通过皮下埋植15、 30和60天后,组织学和形态测定分析验证浸润程度。除此之外,提取大鼠牙槽骨以及植入体周围组织,酶联免疫吸附试验检测肿瘤坏死因子-α和白细胞介素-10表达水平。

结果显示,植物提取物联合MTA可以显着提高材料的最终凝固时间;然而,复合材料并未发生容积改变(P > .05),同时保持着介质的碱性环境和钙离子释放。丙二醇浸膏剂表现出较高的流动性。在24 h和168 h,茜草可以增加针对粪肠球菌的固井效果。组织学结果显示,在所有时间节点,植物提取物组和去离子水组对炎症浸润程度没有明显差异。并且,肿瘤坏死因子-α和白细胞介素-10表达水平在各组间也未见明显差异(P > .05)。

结论:茜草提取物可以提高MTA的抗菌效果,同时并不影响其生物相容性,但会对其理化性能有少量改变。

原始出处

Cavenago BC, Del Carpio-Perochena AE, et al. Effect of Using Different Vehicles on the Physicochemical, Antimicrobial, and Biological Properties of White Mineral Trioxide Aggregate. J Endod. 2017 Mar 17. pii: S0099-2399(16)31069-X. doi: 10.1016/j.joen.2016.12.023.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1894497, encodeId=f0a4189449e60, content=<a href='/topic/show?id=7e2688e517' target=_blank style='color:#2F92EE;'>#HIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8875, encryptionId=7e2688e517, topicName=HIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Mon Oct 02 10:00:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645426, encodeId=c59b1645426c0, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Aug 06 15:00:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330560, encodeId=45b713305608b, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Wed Mar 29 15:00:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368021, encodeId=9849136802163, content=<a href='/topic/show?id=de4912308e7' target=_blank style='color:#2F92EE;'>#MTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12308, encryptionId=de4912308e7, topicName=MTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Wed Mar 29 15:00:00 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
    2017-10-02 yuandd
  2. [GetPortalCommentsPageByObjectIdResponse(id=1894497, encodeId=f0a4189449e60, content=<a href='/topic/show?id=7e2688e517' target=_blank style='color:#2F92EE;'>#HIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8875, encryptionId=7e2688e517, topicName=HIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Mon Oct 02 10:00:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645426, encodeId=c59b1645426c0, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Aug 06 15:00:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330560, encodeId=45b713305608b, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Wed Mar 29 15:00:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368021, encodeId=9849136802163, content=<a href='/topic/show?id=de4912308e7' target=_blank style='color:#2F92EE;'>#MTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12308, encryptionId=de4912308e7, topicName=MTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Wed Mar 29 15:00:00 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
    2017-08-06 mei539
  3. [GetPortalCommentsPageByObjectIdResponse(id=1894497, encodeId=f0a4189449e60, content=<a href='/topic/show?id=7e2688e517' target=_blank style='color:#2F92EE;'>#HIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8875, encryptionId=7e2688e517, topicName=HIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Mon Oct 02 10:00:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645426, encodeId=c59b1645426c0, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Aug 06 15:00:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330560, encodeId=45b713305608b, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Wed Mar 29 15:00:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368021, encodeId=9849136802163, content=<a href='/topic/show?id=de4912308e7' target=_blank style='color:#2F92EE;'>#MTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12308, encryptionId=de4912308e7, topicName=MTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Wed Mar 29 15:00:00 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1894497, encodeId=f0a4189449e60, content=<a href='/topic/show?id=7e2688e517' target=_blank style='color:#2F92EE;'>#HIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8875, encryptionId=7e2688e517, topicName=HIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Mon Oct 02 10:00:00 CST 2017, time=2017-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645426, encodeId=c59b1645426c0, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Sun Aug 06 15:00:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330560, encodeId=45b713305608b, content=<a href='/topic/show?id=c6b455688d1' target=_blank style='color:#2F92EE;'>#抗菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55688, encryptionId=c6b455688d1, topicName=抗菌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/2898B09F0DA89357D0D54A725E611AC7/100, createdBy=fdd32500040, createdName=ms7899726347904398, createdTime=Wed Mar 29 15:00:00 CST 2017, time=2017-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368021, encodeId=9849136802163, content=<a href='/topic/show?id=de4912308e7' target=_blank style='color:#2F92EE;'>#MTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12308, encryptionId=de4912308e7, topicName=MTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb3a261, createdName=liuxiaona, createdTime=Wed Mar 29 15:00:00 CST 2017, time=2017-03-29, status=1, ipAttribution=)]
    2017-03-29 liuxiaona

相关资讯

J Endod:新型高可塑性MTA材料的细胞毒性、生物相容性和生物矿化作用分析

MTA具有极好的生物特性,但其操作性较差,如:ProRoot MTA (Tulsa Dental Products, Tulsa, OK)和white MTA-Angelus (MTA-Ang; Angelus Indústria de Produtos Odontológicos S/A, Londrina, PR, Brazil)。近来,高可塑性MTA-Angelus(MTA-Angelus

J Endod:MTA通过抑制自体吞噬通路抗破骨发生

MTA可以调控骨重建,特别是破骨细胞的分化。然而,MTA抗破骨发生的潜在分子机制还未可知。这篇报道的目的是在体外研究MTA抗破骨发生过程中,自噬通路可能发生的改变以及潜在的机制。

J Endod:MTA促进人牙周膜再生成功的首例临床证据

这篇报道是为了验证MTA在应用于人牙髓治疗过程中,是否能像在动物模型中一样,可以促进根尖周组织的再生。